CLINICAL REPORTS

Management of oral leukoplakia by ablative fractional laser-assisted photodynamic therapy: A 3-year retrospective study of 48 patients

Yi-Lin Yao MD | Yu-Feng Wang PhD | Chen-Xi Li MD | Lan Wu PhD | Guo-Yao Tang PhD

Department of Oral Mucosal Diseases, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai, China

Correspondence
Lan Wu, PhD, and Guo-Yao Tang, PhD, Department of Oral Mucosal Diseases, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology. Email: teana_wu@sina.com and tanggy@shsmu.edu.cn

Abstract
Objectives: This study aimed to review the results of oral leukoplakia (OL) using ablative fractional laser-assisted photodynamic therapy (AFL-PDT) and to further evaluate the risk factors for recurrence and malignant transformation.

Materials and Methods: Forty-eight patients diagnosed with OL using histopathology were enrolled in this study. All patients received one session of AFL-PDT. Therapeutic efficacy was evaluated 1 month posttreatment. Follow-up was scheduled every 3 months in the first year and every 6 months thereafter.

Results: An overall positive response rate of 87.5% (42/48) was achieved, including 62.5% (30/48) complete responses and 25.0% (12/48) partial responses. During the 3-year follow-up period, the recurrence and malignant transformation rates were 37.5% (18/48) and 8.3% (4/48), respectively. Lesions on gingiva/palate seemed to be associated with recurrence ($p < 0.001$; odds ratio [OR]: 1.64, 95% confidence interval [CI]: 1.13–2.37). The severity of epithelial dysplasia ($p = 0.02$; OR: 2.93, 95% CI: 1.96–4.42) and recurrence ($p = 0.016$; OR: 3.14, 95% CI: 2.04–4.84) were associated with a predisposition to malignant transformation.

Conclusions: AFL-PDT is an effective management of OL, but requires close follow-up. OL lesions on the gingiva/palate are predisposed to recurrence. OLs that recur with moderate/severe epithelial dysplasia have a higher risk of transforming into oral squamous cell carcinoma.

KEYWORDS
ablative fractional laser, malignant transformation, oral leukoplakia, photodynamic therapy, recurrence

INTRODUCTION

The World Health Organization (WHO) defined oral leukoplakia (OL) as “a white patch or plaque that cannot be characterised clinically or pathologically as any other disease.” The prevalence of OL is approximately 3%,1,2 of which 10%-36% of cases occur in oral squamous cell carcinoma (OSCC).1,2 Consequently, OL is considered one of the most common oral mucosal diseases and premalignant disorders.

Treatment modalities for OL include scalpel excision, laser therapy, cryotherapy, topical application of bleomycin and vitamin A, and systemic administration of β-carotene, lycopene, and retinoids.3,4 Photodynamic therapy (PDT) is an attractive treatment for OL, since large or multiple lesions can be treated with low toxicity, minimal invasiveness, and high selectivity.5,6 However, the penetration depth of photosensitizers into the lesion is a significant limitation for PDT efficacy.7,8 Ablative fractional laser (AFL) has been proven to be effective...
through in vitro and in vivo studies. AFL is also recommended by the guidelines for topical PDT for enhancing the uptake of topically applied photosensitizers and intensifying PDT response during the treatment of premalignant diseases. One case study has reported that an OL with a large area was successfully treated by AFL-assisted PDT (AFL-PDT) but not by PDT alone, which demonstrated the therapeutic effect of AFL in AFL-PDT. However, the efficacy of AFL-PDT for OL has not been summarized. In this study, we reviewed the results of OL patients who were treated with AFL-PDT and evaluated the therapeutic effects, recurrence, malignant transformation, and associated risk factors.

MATERIALS AND METHODS

Patients

Consecutive OL patients treated at the Department of Oral Mucosal Disease, Shanghai Ninth People's Hospital, between March 2018 and August 2018 were recruited for this study. Approval was obtained from the ethics committee before initiation (2016-115-T64).

Patients with untreated OLs were screened for inclusion. The inclusion criteria were OL as verified by the diagnostic standard and an age range of 18–75 years. The exclusion criteria were pregnancy/lactation, histopathological diagnosis of other mucosal diseases, severe malignancies, and poor general condition.

Treatment procedures

The OL lesion was prepared to facilitate the penetration of 5-aminolevulinic acid (ALA Zhangjiang Pharmaceuticals) before the application of ALA. After local anesthesia, the stratum corneum was carefully removed with AFL (Juehua Medical Devices Co., Ltd.). The following AFL parameters were used: a square pattern with a coverage rate of 9%, wavelength of 10.6 μm, fluence of 15 W/cm², pulse duration of 52.5 ms, interval of 1.0 ms, and spot pitch of 0.6 mm. Vaporised crusts were cleared with saline cotton swabs and subsequently lifted. The prepared 20% ALA gel was applied to the lesion and successively covered with a piece of glutinous rice paper, plastic wrap, and gauze for saliva isolation. A high-potency vacuum device was used for salivary suction. The illumination procedure was performed 3 h after occlusion of the ALA and involved the administration of red light (Yage LED-IB photodynamic therapy instrument Co., Ltd.) at a wavelength of 630 nm, light dose of 180 J/cm², and fluence rate of 100 source. Light was imaged on the lesion surface at a spot of 1-cm diameter for 5 min. Each spot was overlapped with adjacent spots by 3 mm to cover the entire lesion. In each treatment session, the treatment area was limited to 4 cm² or a diameter of 3 cm. Each treatment area underwent one session of AFL-PDT treatment.

Follow-up

Follow-up was performed 1 month postoperatively, every 3 months in the first year, and every 6 months thereafter. The treated area was measured using a periodontal probe and was recorded using a digital camera. An experienced expert in oral mucosal disease performed the clinical examination, including treatment response, clinical recurrence, and malignant transformation.

Therapeutic efficacy was evaluated in terms of the clinical treatment response at 1 month postoperatively and classified as complete response (CR, 100% reduction in lesion size), partial response (PR, more than 30% reduction in lesion size), or no response (NR, less than 30% reduction in lesion size or even worsening).

Clinical recurrence was evaluated at every follow-up, except for the first time, and described as being present or absent. A biopsy was performed once the lesion appeared nonhomogenous, which indicates a higher potential for malignant transformation. Patients completed the follow-up and received treatment once the lesion transformed into OSCC at any time during the study.

Statistical analysis

Logistic regression was used to evaluate the odds ratios (ORs) and associations among the variables. An asymptotic 95% confidence interval (CI) for the OR was calculated. All tests were two-sided, and p < 0.05 were considered statistically significant. All analyses were performed using SPSS version 13.0 (SPSS Inc.).

RESULTS

Patients

A total of 48 patients with OL who met the inclusion criteria and underwent AFL-PDT were enrolled in the study. Of the 48 patients, the population consisted of 62.5% (30/48) female and 37.5% (18/48) male. The patient characteristics at baseline were as follows: average age (SD) of 60.7 (11.9) years; tobacco history (yes/no), 29.2% (14/48)/70.8% (34/48); alcohol history (yes/no), 12.5% (6/48)/87.5% (42/48). Of the lesions, 41.7% (20/48) were located on the margin surface of the tongue, followed by the cheek mucosa (37.5%, 18/48), gingiva (8.3%, 4/48), palate (6.2%, 3/48), dorsal surface of the tongue (4.2%, 2/48), and floor of the mouth (2.1%, 1/48). Mild, moderate, severe, and no dysplasia were observed in 56.3% (27/48), 31.3% (15/48), 8.3% (4/48), and 4.2% (2/48) of the overall OL patient population, respectively.
Treatment response

After one session of AFL-PDT, 87.5% (42/48) of the OL patients achieved an overall positive response, whereas 12.5% (6/48) did not exhibit any change. Among the 42 responders, 30 and 12 showed CR (Figure 1A) and PR (Figure 1B) to AFL-PDT, respectively.

Clinical recurrence

During the 3-year follow-up, 37.5% (18/48) of the OLs recurred, with an average recurrence time of 6.4 months. Recurrence was observed in 30.0% (9/30) CR lesions, 50.0% (6/12) PR lesions, and 50.0% (3/6) NR lesions. The main characteristics of the recurrence group are presented in Table 1. Univariate analyses revealed that sex, smoking, alcohol history, and epithelial dysplasia did not reach statistical significance (p > 0.05). Notably, univariable analyses and Kaplan–Meier curves for time to recurrence (Figure 2) showed that gingiva/palate was significantly associated with recurrence (p < 0.001; OR: 1.64, 95% CI: 1.13–2.37).

Malignant transformation

During the 3-year follow-up period, the cumulative incidence of malignant transformation was 8.3% (4/48). Among them, CR and NR to AFL-PDT was observed in two cases in each condition. The clinicopathological parameters of each patient with malignant transformation are presented in Table 2. Univariate analyses revealed that the severity of epithelial dysplasia (p = 0.02; OR: 2.93, 95% CI: 1.96–4.42) and recurrence (p = 0.016; OR: 3.14, 95% CI: 2.04–4.84) predisposed the patients to malignant transformation.
transformation. No difference was observed in sex, location, and tobacco and alcohol history ($p > 0.05$). Clinical images of a representative patient with malignant transformation are shown in Figure 3.

### DISCUSSION

In a retrospective study evaluating PDT for OL, an overall response rate of 86.2% was achieved, including 55.2% CR and 31.0% PR, following $4.08 \pm 1.73$ PDT
sessions. Other studies also reported a positive response of 72.3%–83.3% in patients who underwent 6–10 sessions of PDT.16,17 The results of this study showed that 87.5% of the lesions responded to only one session of AFL-PDT, which indicates that AFL can greatly improve the effectiveness of PDT treatment for OL, and AFL-PDT shows excellent efficacy in OL treatment. The recurrence rates reported by two retrospective studies18,19 that evaluated AFL for OL were 33.8% during an average 15-month follow-up and 32% in a >6-month follow-up. Studies20,21 evaluating the effectiveness of PDT for OL have reported recurrence rates that ranged from 18.1% to 30.8% during 3–19 months follow-up. Both recurrence rates in AFL and PDT for OL were higher than that in this study (37.5% recurrence during a 3-year follow-up). Compared with AFL and PDT, AFL-PDT may be a more effective management strategy for OL treatment and reducing the risk of OL recurrence.22 In this study, each treatment area was limited to 4 cm² or a diameter of 3 cm. When the lesion area exceeded the size limit, it was divided into multiple smaller areas for treatment. Each treatment area underwent one session of AFL-PDT. This method may confirm the efficacy of AFL-PDT.

Intriguingly, lesions in the gingiva/palate (p < 0.001; OR: 1.64, 95% CI: 1.13–2.37) exhibited a higher risk of recurrence than that of other lesions. Alfonso et al.18 and Yuri et al.23 reported a consistent result, that the gingiva was the most common recurrence site. The gingiva/palate is subjected to friction and pressure when chewing. Furthermore, the mucosa of both sites was too thin to undergo operation with a sufficient safety margin,22 and consequently, gingiva and palate lesions were risk factors for recurrence. Interestingly, among the 18 enrolled lesions on the cheek mucosa in this study, 17 lesions responded to AFL-PDT, and only three lesions recurred. None of the patients developed OSCC. These results suggest that compared to other sites, AFL-PDT is particularly suitable for lesions on the cheek mucosa.

A systematic review and meta-analysis24 suggested that malignant transformation of OL is independent of laser treatment, including AFL, Nd: YAG laser, KTP laser, or diode laser. Based on the possibility of selective destruction of pathological tissues with accumulated photosensitizers, PDT has been successfully used in oncology.25 The malignant transformation rate of this study was 8.3%, which was comparable with the rates reported by other studies.1–2 This study cannot yet evaluate the influence of AFL-PDT on malignant transformation of OL because of the relatively small sample size and short follow-up period.

The severity of dysplasia was a common risk factor for malignant transformation,26,27 which was also verified in this study (p = 0.02; OR: 2.93, 95% CI: 1.96–4.42). In the present study, 22.2% (4/18) of recurrent OLs transformed into OSCC, which was higher than that of non-recurrent OLs (p = 0.016; OR: 3.14, 95% CI: 2.04–4.84). Three of four cases of malignant transformation were found in the margins of the tongue, which is recognized as a high-risk site for OL malignant transformation.28,29 Our findings should remind clinicians to arrange close follow-up for OL recurrence, especially when lesions occur on the margin of the tongue. In the present study, OLs which showed CR to AFL-PDT recurred and even transformed into OSCC. This suggests that clinicians should not take CR patients lightly, and close follow-up is still required.

CONCLUSION

In conclusion, AFL-PDT is an effective management of OL, but requires close follow-up. OL lesions on the gingiva/palate are predisposed to recurrence. OLs that recur and those with moderate/severe epithelial dysplasia have a higher risk of malignant transformation. Randomised controlled studies with larger sample sizes and longer follow-up times are needed to evaluate the influence of AFL-PDT on OL malignant transformation.

ACKNOWLEDGEMENTS

This study was supported by National Natural Science Foundation of China (81970937, 81730030, and 82020108010), Science and Technology Commission of Shanghai Municipality (21S21902000), Clinical Research Funding, Shanghai Municipal Health Commission (202040458), Cross disciplinary Research Fund (JYJC202111) and the Research Discipline Fund (KQYJKX2020) from Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, College of Stomatology.

CONFLICT OF INTERESTS

The authors declare are no conflict of interest.

ORCID

Yi-Lin Yao https://orcid.org/0000-0001-5831-2072
Yu-Feng Wang https://orcid.org/0000-0003-1417-1460
Chen-Xi Li https://orcid.org/0000-0002-7815-8284
Lan Wu https://orcid.org/0000-0001-8286-1063
Guo-Yao Tang https://orcid.org/0000-0003-1150-5613

REFERENCES

1. Chaturvedi AK, Udaltsova N, Engels EA, Katzel JA, Yanik EL, Katki HA, et al. Oral leukoplakia and risk of progression to oral cancer: a population-based cohort study. J Natl Cancer Inst. 2020;112:1047–54.
2. Chuang SL, Wang CP, Chen MK, Su WWY, Su CW, Chen SLS, et al. Malignant transformation to oral cancer by subtype of oral potentially malignant disorder: a prospective cohort study of Taiwanese nationwide oral cancer screening program. Oral Oncol. 2018;87:58–63.
3. Lodi G, Franchini R, Warnakulasuriya S, Varoni EM, Sardella A, Kerr AR, et al. Interventions for treating oral leukoplakia to prevent oral cancer. Cochrane Database Syst Rev. 2016;7:CD001829.
4. Villa A, Woo SB. Leukoplakia—a diagnostic and management algorithm. J Oral Maxillofac Surg. 2017;75:723–34.
5. Li Y, Wang B, Zheng S, He Y. Photodynamic therapy in the treatment of oral leukoplakia: a systematic review. Photodig Ther. 2019;25:17–22.

6. Prazmo E, Mieleczarek A, Kwasyi M, Lapinski M. Photodynamic therapy as a promising method used in the treatment of oral diseases. Adv Clin Exp Med. 2016;25:799–807.

7. Sandberg C, Halldin CB, Ericson MB, Larkö O, Krostad AL, Wennberg AM. Bioavailability of aminolaevulinic acid and methylaminolaevulinate in basal cell carcinomas: a perfusion study using microdialysis in vivo. Br J Dermatol. 2008;159:1170–76.

8. Champeau M, Vignoud S, Mortier L, Mordon S. Photodynamic therapy for skin cancer: how to enhance drug penetration? J Photochem Photobiol B. 2019;197:111544.

9. Haedersdal M, Katsnelson J, Sakamoto FH, Farinelli WA, et al. Enhanced uptake and photoactivation of topical methyl aminolaevulinate after fractional CO2 laser pre-treatment. Lasers Surg Med. 2011;43:804–13.

10. Haak CS, Farinelli WA, Tam J, Doukas AG, Anderson RR, Haedersdal M. Fractional laser-assisted delivery of methyl aminolaevulinate: impact of laser channel depth and incubation time. Lasers Surg Med. 2012;44:787–95.

11. Morton C, Szeimies RM, Sidoroff A, Wennberg AM, Basset-Seguin N, Calzavara-Pinton P, et al. European dermatology forum guidelines on topical photodynamic therapy. Eur J Dermatol. 2015;25:296–311.

12. Zhang Y, Zhang L, Yang D, Zhang G, Wang X. Treatment of oral refractory large area mucosal leukoplakia with CO2 laser combined with photodynamic therapy: case report. Photodiagnostics Photodyn Ther. 2017;20:193–5.

13. McCullough MJ, Prasad G, Farah CS. Oral mucosal malignancy and potentially malignant lesions: an update on the epidemiology, risk factors, diagnosis and management. Aust Dent J. 2010;55(Suppl 1):61–5.

14. Warnakulasuriya S, Ariyawardana A. Malignant transformation of oral leukoplakia: a systematic review of observational studies. J Oral Pathol Med. 2016;45:155–66.

15. Han Y, Xu S, Jin J, Wang X, Liu X, Hua H, et al. Primary clinical evaluation of photodynamic therapy with oral leukoplakia in chinese patients. Front Physiol. 2018;9:1911.

16. Sieroni A, Adamek M, Kawczyk-Krupka A, Mazur S, Ilewich L. Photodynamic therapy (PDT) using topically applied delta-aminolaevulinic acid (ALA) for the treatment of oral leukoplakia. J Oral Pathol Med. 2003;32:330–6.

17. Pietruska M, Sobaniec S, Bernaczyk P, Cholewa M, Pietruski JK, Dolinka E, et al. Clinical evaluation of photodynamic therapy efficacy in the treatment of oral leukoplakia. Photodiagnostics Photodyn Ther. 2014;11:34–40.

18. Mogedas-Vegara A, Hueto-Madrid JA, Chimenos-Kustner E, Bescos-Atín C. The treatment of oral leukoplakia with the CO2 laser: a retrospective study of 65 patients. J Craniomaxillofac Surg. 2015;43:677–81.

19. Ishii J, Fujita K, Munemoto S, Komori T. Management of oral leukoplakia by laser surgery: relation between recurrence and malignant transformation and clinicopathological features. J Clin Laser Med Surg. 2004;22:27–33.

20. Grant WE, Hopper C, Speight PM, MacRobert AJ, Bown SG. Photodynamic therapy of malignant and premalignant lesions in patients with ‘field cancerization’ of the oral cavity. J Laryngol Otol. 1993;107:1140–45.

21. Prasanna SW, Ingle E, Aruna PR, Pravada C, Koteeswaran D, Ganesan S. Photodynamic therapy of oral leukoplakia and oral lichen planus using methylene blue: a pilot study. J Innov Opt Health Sci. 2015;08:1540005.

22. Yao Y, Shi L, Wang Y, Shen X, Ye S, Tang G, et al. Ablative fractional laser-assisted photodynamic therapy vs. ablative fractional laser for oral leukoplakia treatment: a randomized, controlled pilot study. Photodiagnostics Photodyn Ther. 2021;36:102523.

23. Kuribayashi Y, Tsushima F, Sato M, Morita K, Omura K. Recurrence patterns of oral leukoplakia after curative surgical resection: important factors that predict the risk of recurrence and malignancy. J Oral Pathol Med. 2012;41:682–8.

24. de Paula Paglioni M, Migliorati CA, Schausltz Pereira Faustino I, Marix PALA, Roza ALOCC, et al. Laser excision of oral leukoplakia: Does it affect recurrence and malignant transformation? A systematic review and meta-analysis. Oral Oncol. 2020;109:104850.

25. Kwiatkowski S, Knap B, Przystupski D, Saczko J, Kedzierska E, Knap-Czop K, et al. Photodynamic therapy—mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018;106:1098–107.

26. Jayasooriya PR, Dayaratne K, Dissanayake UB, Warnakulasuriya S. Malignant transformation of oral leukoplakia: a follow-up study. Clin Oral Investig. 2020;24:4563–69.

27. Jerjes W, Upile T, Hamdoon Z, Al-Khawaldeh M, Morcos M, Mosse CA, et al. CO2 laser of oral dysplasia: clinicopathological features of recurrence and malignant transformation. Lasers Med Sci. 2012;27:169–79.

28. Shearston K, Fateh B, Tai S, Hove D, Farah CS. Malignant transformation rate of oral leukoplakia in an Australian population. J Oral Pathol Med. 2019;48:530–7.

29. Speight PM, Khurram SA, Kujan O. Oral potentially malignant disorders: risk of progression to malignancy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125:612–27.

---

How to cite this article: Yao Y-L, Wang Y-F, Li C-X, Wu L, Tang G-Y. Management of oral leukoplakia by ablative fractional laser-assisted photodynamic therapy: a 3-year retrospective study of 48 patients. Lasers Surg Med. 2022;54:682–687. https://doi.org/10.1002/lsm.23534